Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celltech Group (NYSE: CLL) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (67)	5/9/2003 11:58:10 AM
From: nigel bates	Read Replies (1) \| Respond to of 123

Since the OGS munch, I got back in to CLL in a small way. Am now considering switching from PDLI into CLL too. Apart from their large wodge of cash (nearly $600m), PDLI have only around a fifth of Celltech's (c.$525m) revenues, and are only temporarily profitable. Moreover, they have nothing in the near term pipeline that stacks up against CDP870. In any event, it will be interesting to see what CLL can squeeze out of the ill-gotten OGS... ... eg, say 3% of the 4000 patent pending protein targets are worth something: a conservative $5m apiece would give $750m....